Sequential metabolism of sesamin by cytochrome P450 and UDP-glucuronosyltransferase in human liver

Drug Metabolism and Disposition

Volumn 39, Issue 9, 2011, Pages 1538-1545

  Yasuda, Kaori ^a   Ikushiro, Shinichi ^a   Kamakura, Masaki ^a   Munetsuna, Eiji ^a   Ohta, Miho ^b   Sakaki, Toshiyuki ^a  

^a TOYAMA PREFECTURAL UNIVERSITY   (Japan)

^b Soai University   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; CYTOCHROME P450; CYTOCHROME P450 2C9; DRUG METABOLITE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 2B7; RECOMBINANT ENZYME; SESAMIN; SESAMIN DICATECHOL; SESAMIN MONOCATECHOL; SESAMIN MONOCATECHOL GLUCURONIDE; SESAMIN MONOCATECHOL METHYLATE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG COMPETITION; DRUG GLUCURONIDATION; DRUG METABOLISM; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CYTOSOL; LIVER METABOLISM; LIVER MICROSOME; MALE; METHYLATION; NONHUMAN; PRIORITY JOURNAL; RAT; SPECIES DIFFERENCE;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CATECHOL O-METHYLTRANSFERASE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DIOXOLES; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; INTESTINE, SMALL; ISOENZYMES; LIGNANS; LIVER; MALE; METHYLATION; MICROSOMES, LIVER; NADP; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS;

RATTUS;

EID: 80051987357     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.039875     Document Type: Article

References (28)

1. Chatterjee P and Franklin M.R. (2003) Human cytochrome p450 inhibition and metabolic- Intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab Dispos 31:1391-1397. (Pubitemid 37310329)
2. Congiu M., Mashford M.L., Slavin JL, and Desmond P.V. (2002) UDP glucuronosyltransferase mRNA levels in human liver disease. Drug Metab Dispos 30:129-134. (Pubitemid 34106530)
3. Court M.H. (2005) Isoform- Selective probe substrates for in vitro studies of human UDP- Selective probe substrates for in vitro studies of human UDPGlucuronosyltransferases. Methods Enzymol 400:104-116.
4. Hamada N., Fujita Y., Tanaka A., Naoi M., Nozawa Y., Ono Y., Kitagawa Y., Tomimori N., Kiso Y, and Ito M. (2009) Metabolites of sesamin, a major lignan in sesame seeds, induce neuronal differentiation in PC12 cells through activation of ERK1/2 signaling pathway. J Neural Transm 116:841-852.
5. Hirata F., Fujita K., Ishikura Y., Hosoda K., Ishikawa T, and Nakamura H. (1996) Hypocholesterolemic effect of sesame lignan in humans. Atherosclerosis 122:135-136. (Pubitemid 26132629)
6. Hirose N., Doi F., Ueki T., Akazawa K., Chijiiwa K., Sugano M., Akimoto K., Shimizu S, and Yamada H. (1992) Suppressive effect of sesamin against 7,12- Dimethylbenz[a]- Dimethylbenz[a]Anthracene induced rat mammary carcinogenesis. Anticancer Res 12:1259-1265.
7. Hirose N., Inoue T., Nishihara K., Sugano M., Akimoto K., Shimizu S, and Yamada H. (1991) Inhibition of cholesterol absorption and synthesis in rats by sesamin. J Lipid Res 32:629-638.
8. Ikeda T., Nishijima Y., Shibata H., Kiso Y., Ohnuki K., Fushiki T, and Moritani T. (2003) Protective effect of sesamin administration on exercise- Induced lipid peroxidation. Int J Sports Med 24:530-534. (Pubitemid 37211221)
9. Izukawa T., Nakajima M., Fujiwara R., Yamanaka H., Fukami T., Takamiya M., Aoki Y., Ikushiro S., Sakaki T, and Yokoi T. (2009) Quantitative analysis of UDP- Glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers. Drug Metab Dispos 37:1759-1768.
10. Kawai Y., Nishikawa T., Shiba Y., Saito S., Murota K., Shibata N., Kobayashi M., Kanayama M., Uchida K, and Terao J. (2008) Macrophage as a target of quercetin glucuronides in human atherosclerotic arteries: implication in the anti- Atherosclerotic mechanism of dietary flavonoids. J Biol Chem 283:9424-9434.
11. Kiso Y. (2004) Antioxidative roles of sesamin, a functional lignan in sesame seed, and it's effect on lipid- And alcohol- And alcoholMetabolism in the liver: a DNA microarray study. Biofactors 21:191-196.
12. Kumagai Y., Wickham K.A., Schmitz DA, and Cho A.K. (1991) Metabolism of methylenedioxyphenyl compounds by rabbit liver preparations. Participation of different cytochrome P450 isozymes in the demethylenation reaction. Biochem Pharmacol 42:1061-1067.
13. Liu Z., Saarinen NM, and Thompson L.U. (2006) Sesamin is one of the major precursors of mammalian lignans in sesame seed (Sesamum indicum) as observed in vitro and in rats. J Nutr 136:906-912.
14. Miyahara Y., Komiya T., Katsuzaki H., Imai K., Nakagawa M., Ishi Y, and Hibasami H. (2000) Sesamin and episesamin induce apoptosis in human lymphoid leukemia Molt 4B cells. Int J Mol Med 6:43-46.
15. Miyake Y., Fukumoto S., Okada M., Sakaida K., Nakamura Y, and Osawa T. (2005) Antioxidative catechol lignans converted from sesamin and sesaminol triglucoside by culturing with Aspergillus. J Agric Food Chem 53:22-27. (Pubitemid 40066464)
16. Miyawaki T., Aono H., Toyoda-Ono Y., Maeda H., Kiso Y, and Moriyama K. (2009) Antihypertensive effects of sesamin in humans. J Nutr Sci Vitaminol (Tokyo) 55:87-91.
17. Moazzami A.A., Andersson RE, and Kamal-Eldin A. (2007) Quantitative NMR analysis of a sesamin catechol metabolite in human urine. J Nutr 137:940-944. (Pubitemid 46596891)
18. Mochizuki M., Tsuchie Y., Nakamura Y, and Osawa T. (2009) Identification and characterization of sesaminol metabolites in the liver. J Agric Food Chem 57:10429-10434.
19. Murray M. (2000) Mechanisms of inhibitory and regulatory effects of methylenedioxyphenyl compounds on cytochrome P450- Dependent drug oxidation. Curr Drug Metab 1:67-84.
20. Nakai M., Harada M., Nakahara K., Akimoto K., Shibata H., Miki W, and Kiso Y. (2003) Novel antioxidative metabolites in rat liver with ingested sesamin. J Agric Food Chem 51:1666-1670.
21. Nakajima M., Suzuki M., Yamaji R., Takashina H., Shimada N., Yamazaki H, and Yokoi T. (1999) Isoform selective inhibition and inactivation of human cytochrome P450s by methylenedioxyphenyl compounds. Xenobiotica 29:1191-1202. (Pubitemid 30019221)
22. Nakano D., Kwak C.J., Fujii K., Ikemura K., Satake A., Ohkita M., Takaoka M., Ono Y., Nakai M., Tomimori N., et al. (2006) Sesamin metabolites induce an endothelial nitric oxide- Dependent vasorelaxation through their antioxidative property- Dependent vasorelaxation through their antioxidative propertyIndependent mechanisms: possible involvement of the metabolites in the antihypertensive effect of sesamin. J Pharmacol Exp Ther 318:328-335.
23. Ogawa H., Sasagawa S., Murakami T, and Yoshizumi H. (1995) Sesame lignans modulate cholesterol metabolism in the stroke- Prone spontaneously hypertensive rat. Clin Exp Pharmacol Physiol Suppl 22:S310-S312. (Pubitemid 26064495)
24. Peñalvo J.L., Heinonen S.M., Aura AM, and Adlercreutz H. (2005) Dietary sesamin is converted to enterolactone in humans. J Nutr 135:1056-1062. (Pubitemid 40645290)
25. Soars M.G., Burchell B, and Riley R.J. (2002) In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J Pharmacol Exp Ther 301:382-390. (Pubitemid 34250317)
26. Uchihashi S., Fukumoto H., Onoda M., Hayakawa H., Ikushiro SI, and Sakaki T. (2011) Metabolism of the c- Fos/activator protein- Fos/activator protein1 inhibitor T- Fos/activator protein1 inhibitor T5224 by multiple human UGT isoforms. Drug Metab Dispos 39:803-813.
27. Usia T., Watabe T., Kadota S, and Tezuka Y. (2005) Metabolite- Cytochrome P450 complex formation by methylenedioxyphenyl lignans of Piper cubeba: mechanism- Cytochrome P450 complex formation by methylenedioxyphenyl lignans of Piper cubeba: mechanismBased inhibition. Life Sci 76:2381-2391. (Pubitemid 40313425)
28. Yasuda K., Ikushiro S., Kamakura M., Ohta M, and Sakaki T. (2010) Metabolism of sesamin by cytochrome P450 in human liver microsomes. Drug Metab Dispos 38:2117-2123.